Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam

Autor: Maarten J. Postma, Herman J. Woerdenbag, Hong Anh T. Tu, Robin de Vries, Shu-Chuen Li, Marinus van Hulst, Hoa H. Le
Přispěvatelé: Pharmaceutical Technology and Biopharmacy, Microbes in Health and Disease (MHD), Methods in Medicines evaluation & Outcomes research (M2O)
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Hepatitis B virus
Hepatitis B vaccine
Cost effectiveness
Economics
Econometrics and Finance (miscellaneous)
drug cost
infection rate
mass immunization
medicine.disease_cause
Quality-adjusted life-year
Acceptability
sensitivity analysis
newborn
Health care
cost benefit analysis
quality adjusted life year
Medicine
controlled study
human
gross national product
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)
outcome assessment
health care economics and organizations
Incremental cost-effectiveness ratio
Actuarial science
Cost–benefit analysis
Affordability
business.industry
Health Policy
cost effectiveness analysis
article
infection prevention
Cost-effectiveness analysis
infection control
Quality-adjusted life year
priority journal
Viet Nam
medical decision making
Cost-effectiveness
chronic hepatitis
hepatitis B
business
hepatitis B vaccine
budget
Zdroj: Value in Health Regional Issues, 1(1), 7-14. HANLEY & BELFUS-ELSEVIER INC
ISSN: 2212-1102
DOI: 10.1016/j.vhri.2012.03.007
Popis: Objectives: To perform acost-effectiveness analysis and to identify the coseffectiveness affordability levels for a newborn universal vaccination program against hepatitis B virus (HBV) in Vietnam. Methods: By using a Markov model, we simulated a Vietnamese birth cohort using 1,639,000 newborns in 2002 and estimated the incremental cost-effectiveness ratios for quality-adjusted life-year gained following universal newborn HBV vaccination. Two types of analyses were performed, including and excluding expenditures on the treatment of chronic hepatitis B and its complications. We used Monte Carlo simulations to examine cost-effectiveness acceptability and affordability from the payer's perspective and constructed a cost-effectiveness affordability curve to assess the costs and health effects of the program. Results: In the base-case analysis, newborn universal HBV vaccination reduced the carrier rate by 58% at a cost of US $42 per carrier averted. From the payer's perspective, incremental cost-effectiveness ratio per quality-adjusted life-year gained was US $3.77, much lower than the 2002 per-capita gross domestic product of US $440. Vaccination could potentially be affordable starting at a US $2.1 million budget. At the cost-effectiveness threshold of US $3.77 per quality-adjusted life-year and an annual budget of US $5.9 million, the probability that vaccination will be both cost-effective and affordable was 21%. Conclusions: Universal newborn HBV vaccination is highly cost-effective in Vietnam. In low-income, high-endemic countries, where funds are limited and the economic results are uncertain, our findings on the cost-effectiveness affordability options may assist decision makers in proper health investments. © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Databáze: OpenAIRE
Externí odkaz: